快速选择HIV-2囊突变的救援疗法与莱纳卡巴维尔含有的治疗方案
Thomas Montrouge1, Mélanie Bertine1,2, Gilles Peytavin3
1Université Paris Cité, Inserm, IAME, F-75018, Paris, France.
概括
莱纳卡帕维尔初步显示对抗多药耐药性HIV-2病毒的有效性. 然而,大多数患者在一年内产生了耐药性突变,无法实现持续的病毒抑制.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 莱纳卡帕维尔是一种新型的囊抑制剂,已批准用于治疗多药耐药性HIV-1.
- 莱纳卡巴维尔在HIV-2感染,特别是多药耐药菌株的疗效尚未得到充分证实.
研究的目的:
- 评估含莱纳卡巴维尔治疗方案的长期疗效和耐药性概况,用于多药耐药性HIV-2患者.
主要方法:
- 对接受 lenacapavir 含有 lenacapavir 的治疗方案的多抗药性 HIV-2 患者的回顾性分析.
- 病毒载荷的监测和药物耐药性突变的评估.
主要成果:
- 在含有lenacapavir的治疗方案中观察到初始病毒载荷的减少.
- 大多数患者在一年后没有达到持续的病毒抑制.
- 在大多数患者中检测到囊抗药性相关突变的出现.
结论:
- 含莱纳卡巴维尔的疗法可能会提供初始益处,但不足以长期管理多药耐药性HIV-2.
- 耐药性突变的发展限制了lenacapavir在这个人群中的持久有效性.
相关概念视频
01:10Retrovirus Life Cycles
45.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.3K
00:36Viral Mutations
32.0K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.0K